Presence of CD34 + in Megakaryocytes in Association With p53 Expression Predicts Unfavorable Prognosis in Low-risk Myelodysplastic Syndrome Patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8806809 Publication Model: Print Cited Medium: Internet ISSN: 1791-7549 (Electronic) Linking ISSN: 0258851X NLM ISO Abbreviation: In Vivo Subsets: MEDLINE
    • Publication Information:
      Publication: <2000- > : Attiki, Greece : International Institute of Anticancer Research
      Original Publication: Athens : Dr. J.G. Delinassios
    • Subject Terms:
      Prognosis*; Antigens, CD34/*genetics ; Myelodysplastic Syndromes/*genetics ; Tumor Suppressor Protein p53/*genetics; Adult ; Aged ; Aged, 80 and over ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Megakaryocytes/metabolism ; Megakaryocytes/pathology ; Middle Aged ; Myelodysplastic Syndromes/metabolism ; Myelodysplastic Syndromes/pathology ; Risk Assessment ; Risk Factors
    • Abstract:
      Background/aim: Although risk stratification using the Prognostic Scores Systems (IPSS, WPSS and IPSS-R) incorporate key information about prognosis of patients with Myelodysplastic syndromes (MDS), patients classified as low-risk may evolve rapidly and aggressively, despite a "favorable" prognostic stratification. The aim of this study was to identify biomarkers for predicting prognosis, and for better stratification and management of these patients.
      Materials and Methods: Expression of CD34 and p53 in megakaryocytes was examined by immunohistochemistry in 71 MDS patients classified as low-risk.
      Results: CD34 staining in megakaryocytes was associated with p53 expression (p=0.0166). CD34 and p53 expression were associated to worse overall survival in patients (p=0.0281).
      Conclusion: The presence of CD34 in megakaryocytes is associated with p53 expression and an adverse prognosis for MDS patients.
      (Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
    • References:
      Haematologica. 2000 Oct;85(10):1117-8. (PMID: 11025619)
      Arch Pathol Lab Med. 2002 Jul;126(7):823-8. (PMID: 12088452)
      Leuk Res. 2010 Dec;34(12):1551-5. (PMID: 20573398)
      Leuk Res. 2011 Jun;35(6):766-70. (PMID: 21367453)
      N Engl J Med. 2011 Jun 30;364(26):2496-506. (PMID: 21714648)
      Histopathology. 2012 Oct;61(4):694-701. (PMID: 22651817)
      Blood. 2012 Sep 20;120(12):2454-65. (PMID: 22740453)
      Am J Clin Pathol. 2012 Dec;138(6):831-6. (PMID: 23161717)
      Br J Haematol. 2013 Mar;160(5):660-72. (PMID: 23297687)
      Haematologica. 2014 Jun;99(6):1041-9. (PMID: 24682512)
      In Vivo. 2014 Nov-Dec;28(6):1077-84. (PMID: 25398802)
      Curr Opin Hematol. 2015 Mar;22(2):146-54. (PMID: 25575032)
      Blood. 2017 May 18;129(20):2818. (PMID: 28522465)
    • Contributed Indexing:
      Keywords: CD34 on megakaryocytes; Myelodysplastic syndromes; low risk; p53 protein expression; prognosis
    • Accession Number:
      0 (Antigens, CD34)
      0 (TP53 protein, human)
      0 (Tumor Suppressor Protein p53)
    • Publication Date:
      Date Created: 20181228 Date Completed: 20190404 Latest Revision: 20200225
    • Publication Date:
      20240628
    • Accession Number:
      PMC6364072
    • Accession Number:
      10.21873/invivo.11472
    • Accession Number:
      30587636